Asana Medical, Inc. CEO Dr. Christine V. Sapan to Present at 2016 BIO International Convention June 8th

MIAMI LAKES, FL – June 1, 2016 – Asana Medical, Inc., (“Asana,” the “Company”), an emerging life science company focused on the development and commercialization of its innovative tissue engineered therapy to treat Inflammatory Bowel Disease (“IBD”), is pleased to announce that CEO Dr. Christine V. Sapan will be presenting at the 2016 BIO International Convention, being held this year at the Moscone Center in San Francisco, CA from June 6^th through June 9^th.  Dr. Sapan is scheduled to present at the Start-Up Stadium venue on June 8^th between 11:00 am – 1:00 pm PT.

Asana’s product, ExtraCellular Matrix Hydrogel (“ECMH”), is a liquid derived from porcine tissue. Ulcerative Colitis, the disease to which Asana’s breakthrough technology will be first applied, is a debilitating disease that renders the colon dysfunctional.  ECMH creates an environment favorable for the body to grow new tissue in place of diseased or damaged tissue.  Extracellular matrix has been proven to be safe and effective in esophageal repair, hernia grafts, vaginal slings, and burn and wound dressings; Asana is leveraging this safe, proven technology to gastrointestinal applications.

Asana recently completed its pivotal preclinical rodent study. This report will be filed with regulatory authorities in support of Asana’s submission for approval to conduct its First-In-Human study.  Dr. Sapan will discuss the results and proprietary interpretations during her presentation.  For those interested in scheduling a one-on-one meeting with Dr. Sapan while at BIO International, please contact Asana Medical, Inc. at (844) 432-7262 extension 105.